S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in
OTCMKTS:IPSEY

Ipsen Stock Forecast, Price & News

$21.20
+0.40 (+1.92 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.20
Now: $21.20
$21.20
50-Day Range
$20.80
MA: $21.79
$22.72
52-Week Range
$9.10
Now: $21.20
$27.10
Volume135 shs
Average Volume4,587 shs
Market Capitalization$7.11 billion
P/E Ratio11.22
Dividend YieldN/A
Beta1.19
Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis and Roche. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
Ipsen logo

Headlines

Ipsen S.A. reports Q3 results
October 23, 2020 |  seekingalpha.com
IPSEN buys back 23,647 shares
September 10, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPSEY
CUSIPN/A
CIKN/A
Phone33-01-58-33-50-00
Employees5,800
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.02 billion
Cash Flow$2.43 per share
Book Value$5.86 per share

Profitability

Miscellaneous

Market Cap$7.11 billion
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.84 out of 5 stars

Medical Sector

1122nd out of 1,968 stocks

Diagnostic Substances Industry

22nd out of 32 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
$21.20
+0.40 (+1.92 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ipsen (OTCMKTS:IPSEY) Frequently Asked Questions

Is Ipsen a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ipsen stock.
View analyst ratings for Ipsen
or view top-rated stocks.

What stocks does MarketBeat like better than Ipsen?

Wall Street analysts have given Ipsen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ipsen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Ipsen's stock been impacted by Coronavirus (COVID-19)?

Ipsen's stock was trading at $14.4150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IPSEY shares have increased by 47.1% and is now trading at $21.20.
View which stocks have been most impacted by COVID-19
.

Who are Ipsen's key executives?

Ipsen's management team includes the following people:
  • Mr. David Loew, CEO & Director (Age 54)
  • Mr. Aymeric Le Chatelier, Exec. VP & Group CFO (Age 52)
  • Dr. Aidan Murphy, Exec. VP of Technical Operations (Age 55)
  • Ms. Eugenia Litz, VP of Investor Relations
  • Mr. Francois Garnier, Exec. VP & Gen. Counsel (Age 59)
  • Mr. Regis Mulot, Exec. VP & Chief HR Officer (Age 55)
  • Mr. Stephan Gagne, Head of New Tokyo Office
  • Ms. Dominique Laymand, Exec. VP of Ethics & Social Responsibility Officer (Age 67)
  • Mr. Benoit Hennion, Exec. VP of Consumer Healthcare (Age 45)
  • Ms. Dominique Bery, Exec. VP of Strategy & Transformation (Age 50)

Who are some of Ipsen's key competitors?

What is Ipsen's stock symbol?

Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY."

How do I buy shares of Ipsen?

Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ipsen's stock price today?

One share of IPSEY stock can currently be purchased for approximately $21.20.

How much money does Ipsen make?

Ipsen has a market capitalization of $7.11 billion and generates $3.02 billion in revenue each year. The company earns $-56,780,000.00 in net income (profit) each year or $1.89 on an earnings per share basis.

How many employees does Ipsen have?

Ipsen employs 5,800 workers across the globe.

What is Ipsen's official website?

The official website for Ipsen is www.ipsen.com.

Where are Ipsen's headquarters?

Ipsen is headquartered at 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650.

How can I contact Ipsen?

Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]


This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.